City-based pharma player, Claris Lifesciences Ltd, said the company has completed the sale of its Global Generic Injectables Business to Baxter International Inc (USA) for an enterprise value of $625 million.
The company will discuss with its advisors and identify the most efficient method of transferring a significant majority of the net proceeds to its shareholder. The company expects to communicate the process before October 15, 2017.
Arjun Handa, Vice-Chairman and MD of Claris Lifesciences Ltd said, “Today, the Claris products and business model’s uniqueness has a significant potential to deliver strong growth. We believe Baxter is the best partner suited to take this platform forward and drive the next phase of growth.”
Source: The Hindu Business Line
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
